Swantje Held

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial

Sebastian Stintzing, Dominik Paul Modest, Lisa Rossius et al. · The Lancet Oncology · 2016 · 410 citations

Cetuximab Versus Folfiri, Gastrointestinal Oncology, Tumour Dynamics +10

FOLFOXIRI Plus Panitumumab As First-Line Treatment of <i>RAS</i> Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)

Dominik Paul Modest, Uwe M. Martens, Jorge Riera‐Knorrenschild et al. · Journal of Clinical Oncology · 2019 · 189 citations

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial

Sebastian Stintzing, Pratyaksha Wirapati, Heinz‐Josef Lenz et al. · Annals of Oncology · 2019 · 189 citations · Full text

Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial

Volker Kunzmann, Jens T. Siveke, Hana Algül et al. · ˜The œLancet. Gastroenterology & hepatology · 2020 · 184 citations

Pancreatic Cancer, Gastrointestinal Oncology, Medicine +9

FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial

Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker et al. · British Journal of Cancer · 2020 · 177 citations · Full text